

8-29-05

Ifa

Attorney Docket No. 5405-304

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re: **Pizzo et al.**

Application No.: **10/817,023**

Group Art Unit:

Filed: **April 2, 2005**

Examiner:

For: **A Novel Adjuvant Capable of Specifically Activating the Adaptive Immune Response**

Date: **August 26, 2005**

Mail Stop AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97(b)**

Sir:


Attached is a list of documents on Form PTO-1449, together with a copy of any listed foreign patent document and/or non-patent literature. A copy of any listed U.S. patent and/or U.S. patent application publication is not provided herewith in accordance with the amendment by the U.S. Patent and Trademark Office to 37 C.F.R. § 1.98(a)(2)(ii) effective October 21, 2004.

This Information Disclosure Statement is submitted in accordance with 37 C.F.R. § 1.97(b), within three months of the filing date of the above-referenced application or before the mailing of a first Office Action on the merits, whichever event occurs last. Therefore, no fee is believed due. However, the Commissioner is hereby authorized to charge any deficiency or credit any overpayment to Deposit Account No. 50-0220.

It is requested that these documents be considered by the Examiner and officially made of record in accordance with the provisions of 37 C.F.R. § 1.56 and Section 609 of the MPEP.

Myers Bigel Sibley & Sajovec, P.A.
P. O. Box 37428
Raleigh, North Carolina 27627
Telephone: (919) 854-1400
Facsimile: (919) 854-1401

Respectfully submitted,



Kenneth D. Sibley
Registration No. 31,665

CERTIFICATE OF EXPRESS MAILING UNDER 37 CFR 1.10


Express Mail Label No.: **EV 675793574 US**

Date of Deposit: **August 26, 2005**

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR § 1.10 on the date indicated above and is addressed to: **Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450**


Amelia Tauchen

Substitute form 1449/APTO		Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/817,023	
		Filing Date	April 2, 2004	
		First Named Inventor	Pizzo et al.	
		Group Art Unit	1632	
		Examiner Name	Unknown	
Sheet	A	Of	Attorney Docket Number	5405-304



U.S. PATENTS AND PATENT PUBLICATIONS				
Examiner Initials*	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document
		Number	Kind Code (if known)	
	1	US- 6,270,758		Staats et al.
	2	US- 6,413,935		Sette et al.
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No.	Foreign Patent Document			Date of Publication of Cited Document MM-DD-YYYY
		Office	Number	Kind Code (if known)	

OTHER NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T
	3	LENNEY et al. "Antimicrobial Action of Compound 48/80 against Protozoa, Bacteria and Fungi." <u>Journal of Pharmaceutical Sciences</u> , 1997. Vol. 66, No. 5, pages 702-705.	
	4	MALAVIYA et al. "Mast Cell modulation of neutrophil influx and bacterial clearance at sites of infection through TNF-alpha." <u>Nature</u> , 1996. Vol 381, pages 77-80.	
	5	PCT International Search Report for International Application No. PCT/US04/10429, Mailed August 12, 2005 (2 pages)	
	6	SIGMA. Compound 48/80, Sigma product number C2313, December 15, 1997, Saint Louis. (2 pages)	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.